Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody-Positive Patients Without Rheumatoid Arthritis.
Julia A FordXinyi LiuAllison A MarshallAlessandra ZaccardelliMaria G PradoCharlene WiyarandBing LuElizabeth W KarlsonPeter H SchurKevin D DeaneJeffrey A SparksPublished in: Arthritis care & research (2020)
Among CCP+ patients without RA, the risk for progression to RA increased substantially with increasing CCP antibody level. This study provides further support for close monitoring for development of RA among CCP+ patients and identifying strategies to mitigate this risk.